This Listing of Claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

Claim 1 (previously presented): A compound represented by the formula:



or a pharmaceutically acceptable salt, prodrug, or ester thereof wherein:

x represents 0, 1 or 2;

t represents either 0 or 1;

R^1 represents hydrogen, $-CH_2SO_2NH_2$, $-CO_2CH_3$, $-CONHCH_3$, $-CON(CH_3)_2$, $-CH_2C(O)NHCH_3$, $-CH_2C(O)N(CH_3)_2$, $-CONH_2$, $-C(CH_3)_2(SH)$, $-C(CH_3)_2(SCH_3)$, $-C(CH_3)_2(S[O]CH_3)$, $-C(CH_3)_2(S[O]_2CH_3)$, alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals and amino acid side chains selected from asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, leucine, isoleucine, allo-isoleucine, tert-leucine, phenylalanine, ornithine, alanine, norleucine, glutamine, valine, threonine, serine, o-alkyl serine, aspartic acid, beta-cyano alanine, and allothreonine side chains;

R^3 represents hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical;

X' represents N, O, and C(R^{17}) wherein R^{17} represents hydrogen and alkyl radicals;

Y and Y', independently represent O, S and NR15 wherein R15 represents hydrogen and radicals as defined for R^3 ;

R^4 represents radicals as defined by R^3 except for hydrogen;

R^6 represents hydrogen and alkyl radicals;

R^{30}, R^{31} and R^{32} represent radicals as defined for R^1, or one of R^1 and R^{30} together with one of R^{31} and R^{32} and the carbon atoms to which they are attached form a cycloalkyl radical; or R^{30} and R^{32} together with the carbon atoms to which they are attached form a three to six-membered cycloalkyl radical; and

R^{33} and R^{34} independently represent hydrogen, radicals as defined for R^3, or R^{33} and R^{34} together with X' represent cycloalkyl, aryl, heterocyclyl and heteroaryl radicals, provided that when X' is O, R^{34} is absent.

Claims 2-65 (canceled)

Claim 66 (previously presented): A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.

Claim 67 (canceled)

Claim 68 (withdrawn): A method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of the composition of Claim 66.

Claim 69 (withdrawn): The method of Claim 68 wherein the retroviral protease is HIV protease.

Claim 70 (withdrawn): A method of treating a retroviral infection comprising administering an effective amount of the composition of Claim 66.

Claim 71 (withdrawn): The method of Claim 70 wherein the retroviral infection is an HIV infection.

Claim 72 (withdrawn): A method for treating AIDS comprising administering an effective amount of the composition of Claim 66.

Claims 73-77 (canceled)

Claim 78 (previously presented): A compound represented by the formula:



or a pharmaceutically acceptable salt, prodrug, or ester thereof wherein:

R^1 represents hydrogen, $-CH_2SO_2NH_2$, $-CO_2CH_3$, $-CONHCH_3$, $-CON(CH_3)_2$, $-CH_2C(O)NHCH_3$, $-CH_2C(O)N(CH_3)_2$, $-CONH_2$, $-C(CH_3)_2(SH)$, $-C(CH_3)_2(SCH_3)$, $-C(CH_3)_2(S[O]CH_3)$, $-C(CH_3)_2(S[O]_2CH_3)$, alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals and amino acid side chains selected from asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, leucine, isoleucine, allo-isoleucine, tert-leucine, phenylalanine, ornithine, alanine, norleucine, glutamine, valine, threonine, serine, o-alkyl serine, aspartic acid, beta-cyano alanine, and allothreonine side chains;

R^3 represents hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical;

R^4 represents radicals as defined by R^3 except for hydrogen;

R^{30}, R^{31} and R^{32} represent radicals as defined for R^1, or one of R^1 and R^{30} together with one of R^{31} and R^{32} and the carbon atoms to which they are attached form a cycloalkyl radical;

R^{33} and R^{34} independently represent hydrogen, radicals as defined for R^3, or R^{33} and R^{34} together with the nitrogen atom to which they are attached represent heterocycloalkyl and heteroaryl radicals; and

Y and Y', independently represent O, S and NR^{15} wherein R^{15} represents hydrogen and radicals as defined for R^3.

Claims 79-125 (canceled)

Claim 126 (previously presented): A pharmaceutical composition comprising the compound of Claim 78 and a pharmaceutically acceptable carrier.

Claim 127 (withdrawn): A method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of the composition of Claim 126.

Claim 128 (withdrawn): The method of Claim 127 wherein the retroviral protease is HIV protease.

Claim 129 (withdrawn): A method of treating a retroviral infection comprising administering an effective amount of the composition of Claim 126.

Claim 130 (withdrawn): The method of Claim 129 wherein the retroviral infection is an HIV infection.

Claim 131 (withdrawn): A method for treating AIDS comprising administering an effective amount of the composition of Claim 126.

Claim 132 (previously presented): A compound represented by the formula:



(III)

or a pharmaceutically acceptable salt, prodrug, or ester thereof wherein:

R^1 represents hydrogen, $-CH_2SO_2NH_2$, $-CO_2CH_3$, $-CONHCH_3$, $-CON(CH_3)_2$, $-CH_2C(O)NHCH_3$, $-CH_2C(O)N(CH_3)_2$, $-CONH_2$, $-C(CH_3)_2(SH)$, $-C(CH_3)_2(SCH_3)$, $-C(CH_3)_2(S[O]CH_3)$, $-C(CH_3)_2(S[O]_2CH_3)$, alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals and amino acid side chains selected from asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, leucine, isoleucine, allo-isoleucine, tert-leucine, phenylalanine, ornithine, alanine, norleucine, glutamine, valine, threonine, serine, o-alkyl serine, aspartic acid, beta-cyano alanine, and allothreonine side chains;

R^3 represents hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical;

Y and Y', independently represent O, S and NR^{15} wherein R^{15} represents hydrogen and radicals as defined for R^3;

R^4 represents radicals as defined by R^3 except for hydrogen; and

R^{30}, R^{31} and R^{32} represent radicals as defined for R^1, or one of R^1 and R^{30} together with one of R^{31} and R^{32} and the carbon atoms to which they are attached form a cycloalkyl radical; or R^{30} and R^{32} together with the carbon atoms to which they are attached form a cycloalkyl radical.

Claims 133-166 (canceled)

Claim 167 (previously presented): A pharmaceutical composition comprising the compound of Claim 132 and a pharmaceutically acceptable carrier.

Claim 168 (withdrawn): A method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of the composition of Claim 167.

Claim 169 (withdrawn): The method of Claim 168 wherein the retroviral protease is HIV protease.

Claim 170 (withdrawn): A method of treating a retroviral infection comprising administering an effective amount of the composition of Claim 167.

Claim 171 (canceled)

Claim 172 (withdrawn): A method for treating AIDS comprising administering an effective amount of the composition of Claim 167.

Claim 173 (canceled)